Evidence map›Paper›PMID 41631093›Full record

ReviewMedComm2026

Inflammation and Cancer: Molecular Mechanisms and Therapeutic Targets.

Xiaodie Liu, Ziyuan Wang, Huirong Zhu, Yicun Han, Qing Ji

Abstract readReview
In one paragraph

Review in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xiaodie LiuDepartment of Medical Oncology & Cancer Institute of Integrative Medicine Shuguang Hospital, Shanghai University of Traditional Chinese Medicine Shanghai China.
Ziyuan WangDepartment of Pathology Shuguang Hospital, Shanghai University of Traditional Chinese Medicine Shanghai China.
Huirong ZhuDepartment of Medical Oncology & Cancer Institute of Integrative Medicine Shuguang Hospital, Shanghai University of Traditional Chinese Medicine Shanghai China.
Yicun HanDepartment of Medical Oncology & Cancer Institute of Integrative Medicine Shuguang Hospital, Shanghai University of Traditional Chinese Medicine Shanghai China.
Qing JiDepartment of Medical Oncology & Cancer Institute of Integrative Medicine Shuguang Hospital, Shanghai University of Traditional Chinese Medicine Shanghai China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammation is a core pathological factor regulating tumor initiation, progression, and therapeutic resistance, and elucidating its molecular crosstalk with tumors is crucial for developing effective clinical therapies. Internal drivers of inflammation-tumor transformation include genomic disorder, epigenetic memory, mitochondrial stress, and metabolic reprogramming, which synergistically initiate carcinogenesis. External factors amplifying tumor progression cover immune dysfunction, stromal fibrosis, microbial dysbiosis, vascular neoplasia, and neurotoxicity, collectively accelerating tumor development. Notably, current therapies such as immunotherapy and chemoradiotherapy often induce inflammatory accumulation, exacerbating chemoresistance and recurrence. However, cell-specific inflammatory signal regulation and the precise balance between anti-inflammatory effects and antitumor efficacy remain understudied, hindering clinical translation of potential strategies. This review systematically organizes the "internal driving force-external attractive force" regulatory network of inflammation-induced tumors, summarizes preclinical validation of inflammatory targets and combined therapy efficacy, and proposes future focus on cell-specific inflammatory signal regulation. It fills the gap in systematically integrating inflammation-tumor interaction mechanisms and provides important theoretical/practical guidance for developing precision anti-inflammatory-antitumor therapies.

Indexed as

drug resistanceinflammationpersonalized therapytherapeutic targettumor

Identifiers

PMID41631093
PMCPMC12860898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.